Broome Oncology Selects Deep Lens’ VIPER™ to Provide Community Cancer Patients With Better, Faster Access to Cancer Trials

COLUMBUS, Ohio & BINGHAMTON, N.Y.--(BUSINESS WIRE)--#AI--Broome Oncology LLC and Deep Lens announced today that the two companies are collaborating on an initiative to rapidly and effectively match patients to precision therapies and clinical studies with Deep Lens’ artificial intelligence-based screening and enrollment platform, called VIPER™. With the upcoming integration of VIPER to Broome Oncology, clinical trial care team members will improve the identification, screening, and matching of patients to precision-based clinical oncology trials in real-time.

“By partnering with Deep Lens we can better provide our patients access to cutting-edge treatments in clinical trials,” said Ronald P. Harris, DO, Medical Director of Research at Broome Oncology. “The VIPER platform will help in trial pre-screening by identifying and matching cancer patients to eligible trials through AI, streamlining this complicated process for our staff.”

Clinical trial recruitment remains challenging with low participation and enrollment due to limited time and resources for physicians and care teams. More than 15,000 oncology clinical trials are actively recruiting patients; yet estimates put the rate of participation as low as three percent of potential trial candidates.

“Identifying cancer patients who could benefit from a clinical trial is a time-consuming process. We have workforce limitations due to the pandemic, as well as data management challenges due to manual search of patient records and office notes, and minimal data integration, all of which has led to inconsistencies in our patient screening, thereby missing opportunities,” said Eswar Pinnamaneni, Clinical Research Manager at Broome Oncology. “We selected Deep Lens and VIPER to help us solve these challenges and streamline our identification and screening process. The combination of VIPER’s artificial intelligence solution, workflow design, communication optimization, and their research coordination services, supplement our team’s efforts, and together, provide us the best opportunity to care for our cancer patients.”

“The partnership with Broome Oncology gives us an opportunity, through technology, to make a significant impact on cancer patients in central New York that are in desperate need of care,” said Dave Billiter, co-founder and CEO at Deep Lens. “VIPER is a catalyst to improve the way care is delivered and it helps cancer care teams and trial coordinators automate and expedite the patient screening process to match the right patient with the right trial at the right time.”

About Broome Oncology LLC

Broome Oncology is the leading provider of oncology and hematology services in Central New York. We have three locations across the southern tier, spanning over two counties. Our staff includes six board-certified physicians, four nurse practitioners, and over 75 support staff, including oncology certified nurses, pharmacists, pharmacy techs, and laboratory techs. Our affiliation with The US Oncology Network, along with industry-leading pharmaceutical and biotech companies, allows us first-hand knowledge of the latest discoveries and revolutionary treatments. Since the establishment of the clinical research department, our mission has been to make cutting-edge cancer treatments accessible to all our patients. Broome Oncology is a private, physician-owned practice, which prides itself on working closely with each patient and family to tailor an individualized plan of care. For more information, visit www.broomeoncology.com.

About Deep Lens

Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows that combine lab, EMR, and genomic data to match cancer patients to clinical trials and precision therapies at the time of diagnosis, accelerating recruitment and compressing study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies. For more information, visit www.deeplens.ai.

Broome Oncology Media Contact:
Dr. Ronald Harris
research@broomeoncology.com
+1 607.763.6850

Deep Lens Media Contact:
Jessica Yingling, Ph.D., President
Little Dog Communications
jessica@litldog.com
+1.858.344.8091